Principia Biopharma Inc. Common Stock
PRNB
PRNB was delisted on the 25th of September, 2020.
45 hedge funds and large institutions have $463M invested in Principia Biopharma Inc. Common Stock in 2018 Q3 according to their latest regulatory filings, with 45 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NLVP
New Leaf Venture Partners
New York
|
+$74.1M |
| 2 |
O
OrbiMed
New York
|
+$73.5M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$58.1M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
+$50.5M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$42M |
Top Sellers
PRNB Hedge Fund Activity: Q3 2018 in Review
45 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Principia Biopharma Inc. Common Stock (PRNB) for Q3 2018, worth a combined $463M.
Buyers outnumbered sellers: 45 funds opened new PRNB positions and 0 closed out — a net gain of 45 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was New Leaf Venture Partners, opening a new position worth an estimated $74.1M.
- 45 institutional investors held Principia Biopharma Inc. Common Stock (PRNB) as of Q3 2018, up from 0 in Q2 2018.
- Funds reported $463M of Principia Biopharma Inc. Common Stock stock for Q3 2018.
- 45 funds opened new Principia Biopharma Inc. Common Stock positions in Q3 2018 and 0 closed out, a net change of +45 holders.
- The largest Principia Biopharma Inc. Common Stock buyer in Q3 2018 was New Leaf Venture Partners, an estimated $74.1M added.
Based on aggregated 13F filings for Q3 2018.